|
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer Clinical research trials and Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer. Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer  Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
For Condition: stage 3B breast cancer,stage 3A breast cancer,Osteoporosis,menopausal symptoms,Quality of Life,stage 1 breast cancer,stage 2 breast cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Oregon Health and Science University
Synopsis: RATIONALE: Raloxifene and exercise may improve bone health and quality of life in breast cancer survivors. Assessing bone health and quality of life may improve the ability to plan treatment. PURPOSE: Randomized clinical trial to study the effectiveness of raloxifene with or without exercise compared with exercise alone in women who have been previously treated for breast cancer.
Details: OBJECTIVES: I. Determine the effects of raloxifene with or without exercise versus exercise alone on bone reabsorption rate, bone formation rate, and bone density in women previously treated for breast cancer. II. Determine the effects of these regimens on the quality of life of these patients. PROTOCOL OUTLINE: This is a randomized, placebo-controlled, multicenter study. Patients are randomized to one of four treatment arms. Arm I: Patients are asked to exercise 5 days a week with instruction. Patients also receive oral placebo once daily. Arm II: Patients receive oral raloxifene once daily. Arm III: Patients are asked to exercise as in arm I. Patients also receive oral raloxifene once daily. Arm IV: Patients receive oral placebo once daily. All patients receive oral calcium supplements once daily. Treatment continues in all arms for 24 months in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and every 3 months during study. PROJECTED ACCRUAL: A total of 240 patients (60 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed breast cancer No metastatic disease At least 3 months but no more than 1 year since prior chemotherapy regimen including doxorubicin or methotrexate and catabolic steroids (to prevent nausea, vomiting, fluid retention, or hypersensitivity reactions) No routine of regular strenuous exercise (more than 90 minutes per day 6 days/week OR 120 minutes per day 4 days/week) Hormone receptor status: - Estrogen and progesterone receptor negative OR - Estrogen and progesterone receptor positive --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: - See Disease Characteristics - Prior adjuvant or neoadjuvant chemotherapy allowed - No concurrent chemotherapy Endocrine therapy: - See Disease Characteristics - No concurrent tamoxifen Radiotherapy: - Prior adjuvant radiotherapy after chemotherapy allowed - No concurrent radiotherapy Surgery: Not specified Other: No concurrent bisphosphonates --Patient Characteristics-- Age: Any age Sex: Female Menopausal status: - Postmenopausal (at diagnosis OR chemotherapy-induced) - No spontaneous menses for more than 6 months with increased follicle-stimulating hormone and decreased estradiol Performance status: Ambulatory Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: - No cardiac problems that would preclude exercise - No unstable angina Pulmonary: - No respiratory problems that would preclude exercise - No chronic obstructive pulmonary disease - No oxygen dependence Other: - No endocrine disease (e.g., parathyroid hormone disorders) that would accelerate bone turnover and loss - No musculoskeletal problems or other disease that would preclude exercise (e.g., movement-limiting arthritis, muscular dystrophy, or chronic fatigue syndrome) - No known cognitive or psychiatric disorders that would preclude study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AnnaSchwartz, Study Chair, Oregon Health and Science University
Oregon Cancer Center
Portland, Oregon, 97201-3098
United States
Additional Information:
Study ID Numbers: CDR0000069229; NCI-H02-0086,OHSU-6312
Study Start Date: March 2001
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00031811
Other Stage 3a Breast Cancer Studies:
1. A School-Based Osteoporosis Prevention Program for Adolescent Girls
2. Encouraging Calcium Absorption and Bone Formation During Early Puberty
3. Lead Exposure, Genetics, and Osteoporosis Epidemiology
4. Therapeutic Touch for Wrist Fractures in Postmenopausal Women
5. Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
Related Studies:
Other stage 3A breast cancer Clinical Trials
Other Oregon Clinical Trials
Other Portland Clinical Trials
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
|
|
|
|
|
|
|
|
